A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease
Phase of Trial: Phase III
Latest Information Update: 14 Feb 2019
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Renal failure
- Focus Therapeutic Use
- Acronyms Dapa-CKD
- Sponsors AstraZeneca
- 14 Dec 2017 New Source identified and integrated (Clinical Trials Registry - India; CTRI2017-08-009535)
- 24 Mar 2017 Planned End Date changed from 1 Nov 2020 to 27 Nov 2020.
- 24 Mar 2017 Planned primary completion date changed from 1 Nov 2020 to 27 Nov 2020.